3- (4- bromo- 2,6- difluorobenzyloxy)- 5- (3- (4- pyrrolidin- 1- ylbutyl)ureido)isothiazole- 4- carboxylic acid amide

inhibits vascular endothelial growth factor receptor-2 tyrosine kinase; structure in first source

Also Known As:

CP 547,632; CP 547632; CP-547,632; CP-547632; CP547,632; CP547632

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Urea: 15015
    - 3-(4-bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide: 3
- Sulfur Compounds: 278
  - Thiazoles: 392
    - 3-(4-bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - 3-(4-bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide: 3

Experts

1.	Cohen, Roger B: 1 article (06/2007)
2.	Cosgriff, Thomas Michael: 1 article (06/2007)
3.	Eisenberg, Peter David: 1 article (06/2007)
4.	Hainsworth, John Daniel: 1 article (06/2007)
5.	Healey, Diane: 1 article (06/2007)
6.	Langer, Corey J: 1 article (06/2007)
7.	Liau, Katherine: 1 article (06/2007)
8.	Madajewicz, Stefan: 1 article (06/2007)
9.	Pierce, Kristen: 1 article (06/2007)
10.	Simon, George Rajan: 1 article (06/2007)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/01/2007 - "CP-547,632 did not increase the objective response rate to chemotherapy alone in patients with advanced non-small cell lung cancer." 06/01/2007 - "A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)." 06/01/2007 - "Patients with stage IIIB/IV or recurrent non-small cell lung cancer receiving first-line chemotherapy were treated with oral daily CP-547,632 in combination with paclitaxel 225 mg/m(2) and carboplatin AUC = 6 every 3 weeks. "
2.	Neoplasms (Cancer) 11/01/2003 - "CP-547,632 is a well-tolerated, orally-bioavailable inhibitor presently under clinical investigation for the treatment of human malignancies." 11/01/2003 - "It also inhibits VEGF-stimulated autophosphorylation of VEGFR-2 in a whole cell assay with an IC(50) value of 6 nM. After oral administration of CP-547,632 to mice bearing NIH3T3/H-ras tumors, VEGFR-2 phosphorylation in tumors was inhibited in a dose-dependent fashion (EC(50) = 590 ng/ml). " 11/01/2003 - "Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy." 03/01/2006 - "The antitumor activity of YM-359445 was also tested in nude mice bearing various established tumors and compared with other VEGFR2 tyrosine kinase inhibitors (ZD6474, CP-547632, CGP79787, SU11248, and AZD2171), a cytotoxic agent (paclitaxel), and an epidermal growth factor receptor tyrosine kinase inhibitor (gefitinib). "
3.	Exanthema (Rash) 06/01/2007 - "Dose-limiting toxicity of CP-547,632 at 250 mg consisted of diarrhea and rash. " 06/01/2007 - "Dose-limiting toxicity of CP-547,632 250 mg by mouth daily in combination with paclitaxel and carboplatin was grade 3 rash and grade 3 diarrhea despite medical intervention. "
4.	Diarrhea 06/01/2007 - "Dose-limiting toxicity of CP-547,632 at 250 mg consisted of diarrhea and rash. " 06/01/2007 - "Dose-limiting toxicity of CP-547,632 250 mg by mouth daily in combination with paclitaxel and carboplatin was grade 3 rash and grade 3 diarrhea despite medical intervention. "

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	Carboplatin (JM8)
3.	Tyrosine Kinase Inhibitors
4.	ErbB Receptors (EGF Receptor)
5.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
6.	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
7.	Cytotoxins (Cytolysins)
8.	Sunitinib (Sutent)
9.	Gefitinib (Iressa)
10.	YM-359445

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Oral Administration